Literature DB >> 20463250

Mucormycosis, pseudallescheriasis, and other uncommon mold infections.

Clifford Quan1, Brad Spellberg.   

Abstract

Serious infections due to non-Aspergillus molds are being encountered with increasing frequency. Factors likely responsible for the rise of these infections include aging populations in countries with advanced medical technologies, the resultant increase in incidence of many cancers, increasingly intensive myeloablative therapies for these cancers, increasingly intensive care for critically ill patients, and increases in the frequency of solid organ and hematopoietic stem cell transplantation. Although diagnostic and therapeutic modalities have improved, mortality rates for invasive mold infections remain high. In this review, we summarize current knowledge about non-Aspergillus mold infections of the chest, with a focus on risk factors, clinical features, diagnosis, and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20463250      PMCID: PMC3266012          DOI: 10.1513/pats.200906-033AL

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  77 in total

1.  Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants.

Authors:  Francisco M Marty; Lisa A Cosimi; Lindsey R Baden
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

2.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

3.  Pseudallescheriasis: a summary of patients from 1980-2003 in a tertiary care center.

Authors:  Yasodah Jayamohan; Julie A Ribes
Journal:  Arch Pathol Lab Med       Date:  2006-12       Impact factor: 5.534

4.  Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections.

Authors:  E J Anaissie; R T Kuchar; J H Rex; A Francesconi; M Kasai; F M Müller; M Lozano-Chiu; R C Summerbell; M C Dignani; S J Chanock; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-10-24       Impact factor: 9.079

5.  Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer.

Authors:  Georgios Chamilos; Edith M Marom; Russell E Lewis; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2005-05-24       Impact factor: 9.079

6.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 7.  Pulmonary mucormycosis: results of medical and surgical therapy.

Authors:  M Tedder; J A Spratt; M P Anstadt; S S Hegde; S D Tedder; J E Lowe
Journal:  Ann Thorac Surg       Date:  1994-04       Impact factor: 4.330

8.  Spectrum of zygomycete species identified in clinically significant specimens in the United States.

Authors:  E Alvarez; D A Sutton; J Cano; A W Fothergill; A Stchigel; M G Rinaldi; J Guarro
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

9.  [Risk factor for invasive zygomycosis in patients with hematologic malignancies].

Authors:  V Rickerts; Angelika Böhme; Gudrun Just-Nübling
Journal:  Mycoses       Date:  2002       Impact factor: 4.377

10.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.

Authors:  Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

View more
  5 in total

Review 1.  The spectrum of fungi that infects humans.

Authors:  Julia R Köhler; Arturo Casadevall; John Perfect
Journal:  Cold Spring Harb Perspect Med       Date:  2014-11-03       Impact factor: 6.915

Review 2.  Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.

Authors:  Joseph P Lynch; David M Sayah; John A Belperio; S Sam Weigt
Journal:  Semin Respir Crit Care Med       Date:  2015-03-31       Impact factor: 3.119

3.  Case Report: Is Surgical Treatment Beneficial for Intracranial Basal Ganglia Cunninghamellamycosis Following Haematopoietic Stem Cell Transplantation?

Authors:  Bixin Xi; Aiguo Liu; Xin Zhao; Yicheng Zhang; Na Wang
Journal:  Front Pediatr       Date:  2022-05-27       Impact factor: 3.569

4.  Granulomatous pododermatitis in the digits caused by Fusarium proliferatum in a cat.

Authors:  Go Sugahara; Akio Kiuchi; Reiko Usui; Ryouichi Usui; Takayuki Mineshige; Junichi Kamiie; Kinji Shirota
Journal:  J Vet Med Sci       Date:  2013-11-08       Impact factor: 1.267

Review 5.  The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance.

Authors:  Md Rezaul Islam; Md Mominur Rahman; Md Tanjimul Ahasan; Nadia Sarkar; Shopnil Akash; Mahfuzul Islam; Fahadul Islam; Most Nazmin Aktar; Mohd Saeed; Md Harun-Or-Rashid; Md Kawsar Hosain; Md Saidur Rahaman; Sadia Afroz; Shabana Bibi; Md Habibur Rahman; Sherouk Hussein Sweilam
Journal:  Environ Sci Pollut Res Int       Date:  2022-08-19       Impact factor: 5.190

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.